Hani Oweira1,2, Arianeb Mehrabi3, Christoph Reissfelder2, Omar Abdel-Rahman4. 1. Center for Visceral and Specialized Tumor Surgery, Hirslanden Medical Center, Zurich, Switzerland. 2. Department of Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. 3. Department of General, Visceral, and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany. 4. Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, T6G 1Z2, Canada. omar.abdelsalam@ahs.ca.
Abstract
OBJECTIVE: To assess the survival outcomes among a contemporary cohort of colorectal cancer patients with isolated synchronous liver or lung metastases treated with or without surgical resection of the metastases. METHODS: Surveillance, epidemiology and end results database has been accessed and cases with isolated liver or lung metastases diagnosed 2010-2015 have been accessed. Kaplan-Meier survival estimates were used to compare overall survival among patients who had or had not undergone metastasectomy. Multivariable Cox regression analysis was then used to assess the impact of metastasectomy on colorectal cancer-specific survival. RESULTS: A total of 16,372 patients with colorectal cancer with isolated liver or lung metastases (M1a disease) were included in the current analysis (including 14,832 patients with isolated liver metastases and 1540 patients with isolated lung metastases). Patients who had undergone surgical resection of liver metastases have better overall survival compared to patients who had not undergone surgical resection of liver metastases (median overall survival: 38.0 months vs. 13.0 months; P < 0.001). Likewise, patients who had undergone surgical resection of lung metastases have better overall survival compared to patients who had not undergone surgical resection of lung metastases (median overall survival: 45.0 months vs. 19.0 months; P < 0.001). In a multivariable Cox regression analysis and among patients with isolated liver metastases, surgery to the metastases was associated with a reduced hazard of death (hazard ratio (HR) 0.567; 95% CI 0.529-0.609; P < 0.001). Likewise, and among patients with isolated lung metastases, surgery to the metastases was associated with a reduced hazard of death (HR 0.482; 95% CI 0.349-0.665; P < 0.001). CONCLUSION: In a contemporary cohort, metastasectomy seems to be associated with improvement in overall and cancer-specific survival among patients with isolated synchronous liver or lung metastases from colorectal cancer. Whether this survival difference is totally ascribed to the effect of metastasectomy or it is the fact that patients who were eligible for surgical resection have limited disease extent and better medical profile (thus, leading to better survival) is unclear from such a population-based study.
OBJECTIVE: To assess the survival outcomes among a contemporary cohort of colorectal cancerpatients with isolated synchronous liver or lung metastases treated with or without surgical resection of the metastases. METHODS: Surveillance, epidemiology and end results database has been accessed and cases with isolated liver or lung metastases diagnosed 2010-2015 have been accessed. Kaplan-Meier survival estimates were used to compare overall survival among patients who had or had not undergone metastasectomy. Multivariable Cox regression analysis was then used to assess the impact of metastasectomy on colorectal cancer-specific survival. RESULTS: A total of 16,372 patients with colorectal cancer with isolated liver or lung metastases (M1a disease) were included in the current analysis (including 14,832 patients with isolated liver metastases and 1540 patients with isolated lung metastases). Patients who had undergone surgical resection of liver metastases have better overall survival compared to patients who had not undergone surgical resection of liver metastases (median overall survival: 38.0 months vs. 13.0 months; P < 0.001). Likewise, patients who had undergone surgical resection of lung metastases have better overall survival compared to patients who had not undergone surgical resection of lung metastases (median overall survival: 45.0 months vs. 19.0 months; P < 0.001). In a multivariable Cox regression analysis and among patients with isolated liver metastases, surgery to the metastases was associated with a reduced hazard of death (hazard ratio (HR) 0.567; 95% CI 0.529-0.609; P < 0.001). Likewise, and among patients with isolated lung metastases, surgery to the metastases was associated with a reduced hazard of death (HR 0.482; 95% CI 0.349-0.665; P < 0.001). CONCLUSION: In a contemporary cohort, metastasectomy seems to be associated with improvement in overall and cancer-specific survival among patients with isolated synchronous liver or lung metastases from colorectal cancer. Whether this survival difference is totally ascribed to the effect of metastasectomy or it is the fact that patients who were eligible for surgical resection have limited disease extent and better medical profile (thus, leading to better survival) is unclear from such a population-based study.
Authors: Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Murielle Mauer; Erik Tanis; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger Journal: Lancet Oncol Date: 2013-10-11 Impact factor: 41.316
Authors: J Zabaleta; B Aguinagalde; M G Fuentes; N Bazterargui; J M Izquierdo; C J Hernández; J M Enriquez-Navascués; J I Emparanza Journal: Eur J Surg Oncol Date: 2011-07-02 Impact factor: 4.424
Authors: Shimul A Shah; Riad Haddad; Wigdan Al-Sukhni; Robin D Kim; Paul D Greig; David R Grant; Bryce R Taylor; Bernard Langer; Steven Gallinger; Alice C Wei Journal: J Am Coll Surg Date: 2006-01-18 Impact factor: 6.113
Authors: Suna Cokmert; Hulya Ellidokuz; Lutfiye Demir; Mehmet Fuzun; Ibrahim Astarcioglu; Deniz Aslan; Ugur Yilmaz; Ilhan Oztop Journal: Asian Pac J Cancer Prev Date: 2014
Authors: John Primrose; Stephen Falk; Meg Finch-Jones; Juan Valle; Derek O'Reilly; Ajith Siriwardena; Joanne Hornbuckle; Mark Peterson; Myrddin Rees; Tim Iveson; Tamas Hickish; Rachel Butler; Louise Stanton; Elizabeth Dixon; Louisa Little; Megan Bowers; Siân Pugh; O James Garden; David Cunningham; Tim Maughan; John Bridgewater Journal: Lancet Oncol Date: 2014-04-07 Impact factor: 41.316
Authors: Soohyeon Lee; Young Soo Park; Jwa Hoon Kim; Ah Reum Lim; Myung Han Hyun; Boyeon Kim; Jong Won Lee; Saet Byeol Lee; Yeul Hong Kim Journal: Cancers (Basel) Date: 2022-09-28 Impact factor: 6.575